Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, TRI

Global Alzheimer's Platform (GAP) Foundation's GAP-Net Site Optimization Conference Unites 63 Leading Research Sites to Accelerate Alzheimer's Disease Clinical Trials, Feb. 21 - 23


LAS VEGAS, Feb. 22, 2018 /PRNewswire/ -- The brightest minds in Alzheimer's research are meeting in Las Vegas for the Global Alzheimer's Platform Foundation's GAP-Net Site Optimization Conference from Feb 21 ? 23. GAP-Net is a first-of-its-kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer's disease. GAP-Net currently has 63 leading academic and private research site partners throughout North America.

Global Alzheimer's Platform logo (PRNewsFoto/Global Alzheimer's Platform Fou)

The goal of the conference is to provide GAP-Net sites and partners with an idea-sharing platform and the opportunity to discuss challenges, best practices, and strategies. Sites can also share and collaborate on activities at the trans-national, regional and local level. It is the second time this conference will be held after the huge success of the inaugural conference in Orlando, May 2017.

"After the wonderful feedback we received from participants at our first conference, the decision to host another was a question of when, not if," said John Dwyer, President of the Global Alzheimer's Platform Foundation. "The chance to bring North America's most renowned researchers and clinical trial sites together is invaluable in our mission of speeding up the clinical trial process and ultimately finding a cure for Alzheimer's."

Expected conference outcomes include: breaking results of emerging recruiting strategies; proven methods for successful community outreach; shared site start-up best practices and metric alignment; coordination of social and digital media policies; and outreach strategies aimed at both recruiting through primary care physicians and enhancing underserved minority representation in clinical trials.

For more information about the GAP-Net Site Optimization Conference, click here. To get the latest news from the conference as it happens, follow #GAPNetOptCon on Twitter.

Tweet for Media:
The Global Alzheimer's Platform's GAP-Net Site Optimization Conference, led by @dwyerjohnjr, is underway in #LasVegas. GAP-Net is 63 leading #research sites coming together in the fight against #Alzheimers globalalzplatform.org/gap_net_opt_con #GAPNetOptCon

Note to Editors
For interviews with GAP representatives and/or GAP-Net researchers, please contact Brianne Miller at: (650) 575-7727 or [email protected].

About Global Alzheimer's Platform Foundation (GAP)
GAP is a patient-centric, non-profit dedicated to speeding the delivery of innovative medicines to those in need by reducing the time and cost of Alzheimer's disease clinical trials. GAP formed a unique and growing network of 59 leading research centers across the U.S. and Canada to help optimize their operations. GAP launched a community-based recruitment model and an online platform designed to accelerate trial recruitment and increase minority representation in research.  Based in Washington D.C., GAP was created by UsAgainstAlzheimer's and the Global CEO Initiative (CEOi) in 2015. To learn more about the GAP, please visit globalalzplatform.org.

Media Contact:
Brianne Miller
Landis Communications Inc.
(650) 575-7727
[email protected]
www.landispr.com

 

SOURCE Global Alzheimer's Platform Foundation


These press releases may also interest you

at 09:50
Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 Phase 1/2 clinical trial in Spinal Muscular Atrophy (SMA) Type I at the American...

at 09:47
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human...

at 09:45
Pleio, Inc. and FountainRx announce their partnership to provide a concierge-level experience to specialty pharmacy patients. The two companies are launching a program to provide patients with human-driven support as they onboard onto their specialty...

at 09:45
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech , a clinical stage pharmaceutical company with a...

at 09:41
Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in...

at 09:35
Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively. CancerVision and...



News published on and distributed by: